abstract：:Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a P...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Sankaranarayanan J,Reardon T,Olsen KM

更新日期：2014-10-01 00:00:00

abstract：:This paper acknowledges the difficulties of providing access to innovative drugs in some jurisdictions under the patent system and it contributes to the current debate on mechanisms aimed at facilitating such access. We employ a highly stylized static model of two markets (North and South) to analyse the conditions un...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoñanzas F,Rodríguez-Ibeas R,Juárez-Castelló CA

更新日期：2014-10-01 00:00:00

abstract：AIMS:To estimate the direct and indirect costs associated with disability due to multiple sclerosis (MS) in Poland. METHODS:Recently a cost-of-illness study was conducted in the Czech Republic, involving 909 patients with different levels of disability (the COMS study). Data on resource use from this trial was extrapo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Szmurło D,Fundament T,Ziobro M,Kruntorádová K,Doležal T,Głogowski C

更新日期：2014-06-01 00:00:00

abstract：:This article systematically appraises the findings and conclusions derived from six recent studies of the economic impact and relative value of using percutaneous ventricular assist devices to render short-term hemodynamic support to high-risk patients with particular attention to the settings of cardiogenic shock and...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Maini B,Scotti DJ,Gregory D

更新日期：2014-06-01 00:00:00

abstract：:The pharmaceutical sector has been established as the primary cost driver in health. The scope of this paper is to explore the drivers of pharmaceutical expenditure in Cyprus by decomposing sales and assessing impact of prices, volumes and substitution effect. We used a statistical approach to decompose the growth of ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Petrou P

更新日期：2014-04-01 00:00:00

abstract：:The European Quality of Life-5 Dimensions Questionnaire (EQ-5D) is the most common instrument to value health outcomes under the patient's perspective. Several studies have investigated whether observed changes are meaningful to patients, using a variety of approaches to estimate the minimum clinically important diffe...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Coretti S,Ruggeri M,McNamee P

更新日期：2014-04-01 00:00:00

abstract：:Evaluation of: Levin LA, Wallentin L, Bernfort L et al. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes results from the PLATO trial. Value Health 16(4), 574-580 (2013). Antiplatelet therapy is considered essential treatment for acute coronary syndromes with or...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： De Franco AC,Oldridge N

更新日期：2014-02-01 00:00:00

abstract：:In recent years, the quest for more comprehensiveness, structure and transparency in reimbursement decision-making in healthcare has prompted the research into alternative decision-making frameworks. In this environment, multi-criteria decision analysis (MCDA) is arising as a valuable tool to support healthcare decisi...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Diaby V,Goeree R

更新日期：2014-02-01 00:00:00

abstract：:The Dutch basic health insurance is based on the principles of regulated competition. This implies that insurers and providers compete on price and quality while the regulator sets certain rules to achieve public objectives such as solidarity. Two regulatory aspects of this scheme are that insurers are not allowed to ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： van Kleef RC,van de Ven WP,van Vliet RC

更新日期：2013-12-01 00:00:00

abstract：:We surveyed US-based leaders in health economics and outcomes research (HEOR) departments in drug and device companies to examine their views on the state of the field. We created a questionnaire that was emailed to 123 US-based senior HEOR professionals at 54 companies. Of the 123 recipients, 74 (60%) completed the s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Neumann PJ,Saret CJ

更新日期：2013-10-01 00:00:00

abstract：:Prostate cancer is the most common non-skin cancer in American men, and prostate-specific antigen (PSA) testing is its common screening procedure. In May 2012, the US Preventive Services Task Force recommended against PSA-based screening. These recommendations contradict the current recommendations of other organizati...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Garg V,Gu NY,Borrego ME,Raisch DW

更新日期：2013-06-01 00:00:00

abstract：:Electronic medical records (EMRs) have become a common source of data for outcomes research. This review discusses trends in EMR data use for outcomes research as well as strengths and limitations, and likely future developments to help optimize value and use of EMR data for outcomes research. EMR-based studies report...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lin J,Jiao T,Biskupiak JE,McAdam-Marx C

更新日期：2013-04-01 00:00:00

abstract：:Interest is rising in measuring subjective health outcomes, such as treatment outcomes that are not directly quantifiable (functional disability, symptoms, complaints, side effects and health-related quality of life). Health economists in particular have applied probabilistic choice models in the area of health evalua...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Arons AM,Krabbe PF

更新日期：2013-02-01 00:00:00

abstract：:At least 14% of cancer patients live with minor children. Being a parent with cancer has far-reaching consequences for individual treatment decision-making and quality of life in patients and their families. Even though the majority of children and adolescents do not show clinically relevant symptoms of psychopatholog...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Krauel K,Simon A,Krause-Hebecker N,Czimbalmos A,Bottomley A,Flechtner H

更新日期：2012-12-01 00:00:00

abstract：:This article reviews the literature reporting empirically determined symptom clusters in patients with metastatic cancer. A literature search was conducted on symptom clusters within heterogeneous metastatic cancer patient populations using MEDLINE, EMBASE, and CINAHL. Studies examining predetermined symptom clusters ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Thavarajah N,Chen E,Zeng L,Bedard G,Di Giovanni J,Lemke M,Lauzon N,Zhou M,Chu D,Chow E

更新日期：2012-10-01 00:00:00

abstract：:The European Organisation for Research and Treatment of Cancer (EORTC) 50th Anniversary Conference was held on the 15-16 March in Brussels, Belgium. More than 1100 participants (including EORTC members and staff, national research organizations, health authorities, patient advocacy groups, European Commission, cancer ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Bean J,Bottomley A,Meunier F

更新日期：2012-08-01 00:00:00

abstract：:Alzheimer's disease is a neurodegenerative disorder characterized by cognitive and behavioral deficits. Donepezil and memantine are two medications used to treat the symptoms of cognitive decline in Alzheimer's disease. A modeled cost-effectiveness analysis found that treatment with donepezil to be less costly and mor...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Oremus M,Tarride JE

更新日期：2012-06-01 00:00:00

abstract：:Parkinson's disease (PD) is the second most common neurological disease affecting older adults. Consequently, this disease should be a focus among payers, with increasing utilization of newer premium-priced patent-protected add-on therapies to stabilize or even improve motor function over time. However, expenditure ca...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Brkicic LS,Godman B,Voncina L,Sovic S,Relja M

更新日期：2012-06-01 00:00:00

abstract：:Reconciliation refers to the process through which two or more independent forward translations are merged into one single translation. This critical step in the translation process is difficult to formalize. The purpose of this review is to analyze how reconciliation is specified in leading guidelines for the transla...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Koller M,Kantzer V,Mear I,Zarzar K,Martin M,Greimel E,Bottomley A,Arnott M,Kuliś D,ISOQOL TCA-SIG.

更新日期：2012-04-01 00:00:00

abstract：:The 15th International Symposium for Health Information Management Research (ISHIMR) was organized jointly by University Hospital Zurich (Switzerland), the University of St Gallen (St Gallen, Switzerland) and the University of Sheffield (Sheffield, UK). Participants included researchers, healthcare professionals, heal...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Bath PA,Sen BA,Raptis DA,Mettler T

更新日期：2012-02-01 00:00:00

abstract：:In this article, we will focus on how preferences and utilities are measured, including the strengths and limitations of various approaches, discuss their use in estimating quality-adjusted life-years (QALYs) and make some recommendations for further research. Preferences are either measured using direct (visual analo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Revicki DA,Lenderking WR

更新日期：2012-02-01 00:00:00

abstract：:The second symposium of the European Organisation for Research and Treatment of Cancer took place in September 2011 at the European Parliament in Brussels (Belgium). The aim of the symposium was to discuss a wide range of topics in health-related quality of life, symptom research and cancer clinical trials, including ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Dormer L

更新日期：2011-12-01 00:00:00

abstract：AIMS:To quantify the relationship between the timing of gastroesophageal reflux disease (GERD) symptoms and the burden of illness. PATIENTS & METHODS:Data from the 2010 National Health and Wellness Survey were used. Regression analyses compared non-GERD controls with GERD patients with diurnal symptoms, nocturnal symp...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wagner JS,DiBonaventura MD,Balu S,Buchner D

更新日期：2011-12-01 00:00:00

abstract：:The assessment of longitudinal change in subjective patient-reported outcomes such as health-related quality of life (HRQoL) is a key component of many clinical and research evaluations. A major goal of measuring patient-reported HRQoL is to determine to what extent changes in HRQoL reports over time represent true ch...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hamidou Z,Dabakuyo TS,Bonnetain F

更新日期：2011-10-01 00:00:00

abstract：:The Institute for Quality and Efficiency in Health Care in Germany makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effects in each therapeutic area. The analysis requires, when applicable, calculation of savings from avoided clinical events and increased f...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gandjour A,Gafni A

更新日期：2011-08-01 00:00:00

abstract：:Quality of life has become an important end point in clinical trials and academic studies. The questionnaires developed by the European Organisation for Research and Treatment of Cancer Quality of Life Group are widely used to measure quality of life in cancer patients. The expanding geographical coverage of current s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kuliś D,Arnott M,Greimel ER,Bottomley A,Koller M,European Organisation for Research and Treatment of Cancer Quality of Life Group.

更新日期：2011-06-01 00:00:00

abstract：:Cutaneous melanoma (CM) is a highly curable skin cancer of melanocytes if diagnosed early. Unfortunately, its invasion into the deeper dermis increases the risk of it spreading to the lymph nodes and distant organs. Spread of metastatic melanoma (MM) to other organs is among one of the most dangerous conditions that i...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hegde UP,Chakraborty N,Mukherji B,Grant Kels JM

更新日期：2011-04-01 00:00:00

abstract：:Health technology assessment (HTA) has become an integral part of decision-making on the coverage of new health technologies in most health systems in the developed world. In recent years, pressure to involve patients and members of the public in HTA has grown. In this article, we summarize findings from peer-reviewed...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Menon D,Stafinski T

更新日期：2011-02-01 00:00:00

abstract：:Lung cancer is a leading cause of cancer deaths for both men and women across the world. In the past, studies on lung cancer have focused on traditional end points such as survival, disease-free survival or local control. More recently, investigators have begun to appreciate the importance of health-related quality-of...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Siddiqui F,Konski AA,Movsas B

更新日期：2010-12-01 00:00:00

abstract：:Economists' approaches to priority setting focus on the principles of opportunity cost, marginal analysis and choice under scarcity. These approaches are based on the premise that it is possible to design a rational priority setting system that will produce legitimate changes in resource allocation. However, beyond is...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Peacock SJ,Mitton C,Ruta D,Donaldson C,Bate A,Hedden L

更新日期：2010-10-01 00:00:00

abstract：:Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no internationa...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hirsch EB,Tam VH

更新日期：2010-08-01 00:00:00

abstract：:Differential item functioning (DIF) analyses are used to determine whether certain groups respond differently to a particular item of a test or questionnaire; however, these do not explain the reasons for observed response differences. Many studies have used external reviews of items, sometimes using blinded reviewers...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Scott NW,Fayers PM,Aaronson NK,Bottomley A,de Graeff A,Groenvold M,Gundy C,Koller M,Petersen MA,Sprangers MA,EORTC Quality of Life Group.,Quality of Life Cross-Cultural Meta-Analysis Group.

更新日期：2010-06-01 00:00:00

abstract：:Cancer patient satisfaction assessment is increasingly considered, owing to the need to assess evolving patterns of care organization and delivery or to test new cancer treatments and interventions. This article reviews cancer patient satisfaction questionnaires using key methodological criteria. In total, 17 patient ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Brédart A,Sultan S,Regnault A

更新日期：2010-04-01 00:00:00

abstract：:The Resonance metallic stent is a new wire-based ureteral stent that was initially developed for patients with malignant ureteral obstruction. Potential advantages over traditional stents include resistance to encrustation and to external compression, allowing for increased dwell times and the maintenance of upper tra...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Polcari AJ,Hugen CM,López-Huertas HL,Turk TM

更新日期：2010-02-01 00:00:00

abstract：:A review was undertaken to identify relevant and appropriate heath-utility estimates for patients with atrial fibrillation who had stroke and to appraise them against the published requirements for several countries' Health Technology Assessment agencies: Australia (Pharmaceutical Benefits Advisory Committee), Canada ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lloyd A,Wild D,Gallop K,Cowell W

更新日期：2009-12-01 00:00:00

abstract：AIM:Limitations of vitamin K antagonists (VKAs) include frequent monitoring, dietary restrictions and drug interactions. This study conducted an indepth exploration of perspectives of VKA therapy in respondents with atrial fibrillation or venous thromboembolism. METHODS:A total of 60 respondents, recruited from the UK...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wild D,Murray M,Donatti C

更新日期：2009-10-01 00:00:00

abstract：:Chronic obstructive pulmonary disease is a progressive disease of the airways in which respiratory symptoms aggravate transitorily during disease exacerbations. The treatment of the disease in its stable state is the most important factor in reducing related morbidity, but exacerbation therapy might also impact on sub...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoniu SA

更新日期：2009-08-01 00:00:00

abstract：:Skin diseases are among the most common health problems worldwide and are associated with a considerable burden. The burden of skin disease is a multidimensional concept that encompasses psychological, social and financial consequences of the skin disease on the patients, their families and on society. Chronic and inc...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Basra MK,Shahrukh M

更新日期：2009-06-01 00:00:00

abstract：OBJECTIVE:Otitis media (OM) is an inflammation of the middle ear. It is very common and associated with serious complications, including hearing loss. This study aimed to estimate the treatment costs of OM in Australia and the associated burden of disease (in disability-adjusted life-years). METHODS:Little Australia-w...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Taylor PS,Faeth I,Marks MK,Del Mar CB,Skull SA,Pezzullo ML,Havyatt SM,Coates HL

更新日期：2009-04-01 00:00:00

abstract：:It is a continual challenge trying to improve the quality of prescribing while concurrently trying to address increasing pharmaceutical development, utilization and expenditure. National and regional reforms and initiatives in Sweden have moderated growth in ambulatory drug expenditure to 2.7% per annum in recent year...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Godman B,Wettermark B,Hoffmann M,Andersson K,Haycox A,Gustafsson LL

更新日期：2009-02-01 00:00:00